Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01-31 in 4mo
ESTIMATED |
READOUT
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in
Phase 2 · Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma |
Hoffmann-La Roche | Obinutuzumab, Glofitamab, Gemcitabine, O |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-02
Sponsor-projected date — can change
|